DelveInsight’s “Dilated Cardiomyopathy Market Report” delivers an in-depth analysis of the evolving DCM landscape, including historical and projected epidemiological data across major geographies such as the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. The report explores current treatment approaches involving ACE inhibitors, beta-blockers, ARNI, and device-based therapies like ICDs and CRT. It also highlights gaps in diagnosis, limited disease-modifying therapies, and the growing interest in gene-targeted and regenerative treatments.
With novel agents under development and improved understanding of the genetic basis of DCM, the market is primed for innovation. The report offers valuable insights into key market drivers, ongoing clinical trials, unmet needs, and the pharmaceutical and biotech companies working to redefine care standards. It is a critical resource for healthcare providers, researchers, and investors looking to engage with the rapidly evolving DCM treatment landscape.
Some of the Key Facts of the Dilated Cardiomyopathy Market Report:
• In 2023, the dilated cardiomyopathy market size in the 7MM was approximately USD 464 million, projected to grow through 2034.
• The EU4 and UK market was valued at USD 100 million in 2023, contributing about 22% of the total 7MM market.
• Within the EU4 and UK, Germany led the market (USD 25.6M), followed by France (USD 20.8M) and the UK (USD 20.7M).
• Renin-angiotensin system inhibitors held the largest market share among current therapies, generating around USD 147 million in 2023.
• The prevalent DCM population in the 7MM was estimated at ~3 million in 2023, with the US accounting for 45%, EU4 and UK 43%, and Japan 12%.
• The US represented about 52% of all diagnosed DCM cases, expected to rise through 2034.
• In 2023, EU4 and the UK had roughly 402.5K diagnosed cases, projected to change during the forecast period.
• In the US, 194K cases were linked to genetic or familial causes, and 360K to non-familial factors in 2023, both expected to increase by 2034.
• In June 2025, Nuevocor announced FDA clearance of its IND application for NVC-001, an AAV-based gene therapy targeting LMNA-related dilated cardiomyopathy (LMNA DCM). A Phase I/II open-label, dose-escalation trial is set to begin.
• In March 2025, Alnylam Pharmaceuticals announced moderated poster presentations of new data from the HELIOS-B Phase III trial, evaluating vutrisiran for treating ATTR amyloidosis with cardiomyopathy (ATTR-CM) in a patient population representative of today’s cases.
• In March 2025, Intellia Therapeutics announced that the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to nexiguran ziclumeran (nex-z, also known as NTLA-2001) for treating transthyretin (ATTR) amyloidosis with cardiomyopathy (ATTR-CM).
• In March 2025, Alnylam Pharmaceuticals announced FDA approval of the supplemental New Drug Application (sNDA) for its RNAi therapeutic, AMVUTTRA® (vutrisiran), for treating the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality, hospitalizations, and urgent heart failure visits.
• In February 2025, BridgeBio Pharma received European approval for acoramidis, a drug treating cardiomyopathy caused by transthyretin amyloidosis (ATTR), a rare metabolic condition. The approval strengthens BridgeBio’s position to compete with Pfizer’s blockbuster drug, currently the standard treatment for ATTR.
• In November 2024, Alnylam Pharmaceuticals (ALNY) announced that the FDA has accepted its supplemental new drug application (sNDA) for review, seeking label expansion of Amvuttra (vutrisiran) to treat ATTR amyloidosis with cardiomyopathy (ATTR-CM).
• Leading companies in the dilated cardiomyopathy market include Pfizer, Capricor Therapeutics, MyoKardia, Cumberland Pharmaceuticals, Berlin Cures, and others.
• Emerging acute dilated cardiomyopathy drugs include Danicamtiv (MYK-491), BC007, DYSCORBAN (ifetroban), and others.
• The increasing prevalence of dilated cardiomyopathy and ongoing advancements in therapeutic options are driving the demand for more effective treatment approaches.
To know in detail about the dilated cardiomyopathy market outlook, drug uptake, treatment scenario, and epidemiology trends, click here: Dilated Cardiomyopathy Market Forecast
Dilated Cardiomyopathy Overview
Dilated Cardiomyopathy (DCM) is a type of cardiomyopathy in which the heart’s ventricles, particularly the left ventricle, become enlarged and weakened, leading to reduced pumping efficiency and eventual heart failure. It can be inherited (familial DCM) or acquired through factors such as infections, toxins, autoimmune responses, or unknown (idiopathic) origins. DCM may present with symptoms like fatigue, breathlessness, arrhythmias, or swelling in the legs and feet, and often progresses silently until heart function is significantly compromised.
Diagnosis is typically confirmed through echocardiography, MRI, and sometimes genetic testing. Management is complex and requires a multidisciplinary approach, including medications, lifestyle modification, device therapy, or even heart transplantation in advanced stages.
Get a free sample of the dilated cardiomyopathy market report with key insights and emerging therapies here: https://www.delveinsight.com/report-store/dilated-cardiomyopathy-market-forecast
Dilated Cardiomyopathy Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Dilated Cardiomyopathy Epidemiology Segmentation:
The Dilated Cardiomyopathy epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by:
• Total dilated cardiomyopathy prevalence
• Total diagnosed dilated cardiomyopathy prevalence
• Gender-specific cases of dilated cardiomyopathy
• Familial and non-familial cases of dilated cardiomyopathy
Download the report to understand which factors are driving dilated cardiomyopathy epidemiology trends @ Dilated Cardiomyopathy Epidemiology Forecast
Dilated Cardiomyopathy Drugs Uptake and Pipeline Development Activities
The Dilated Cardiomyopathy drugs uptake section examines the rate at which newly launched or upcoming potential drugs are being adopted in the Dilated Cardiomyopathy market during the study period. This analysis covers drug uptake, patient adoption of therapies, and the sales performance of each drug.
Additionally, the therapeutics assessment section highlights the drugs with the most rapid uptake, shedding light on the factors driving their widespread use. It also provides a comparative analysis of these drugs based on their market share.
The report further delves into the Dilated Cardiomyopathy pipeline development activities, offering key insights into various therapeutic candidates in different stages of development and the major companies behind these innovations. It also covers recent collaborations, acquisitions, mergers, licensing agreements, patent details, and other critical information related to emerging therapies.
Dilated Cardiomyopathy Market Outlook
The treatment landscape for Dilated Cardiomyopathy is currently dominated by pharmacological and device-based interventions. Core drug classes include diuretics, inotropes, beta-blockers, ACE inhibitors, ARBs, mineralocorticoid receptor antagonists, and anticoagulants, tailored to symptom severity and patient profiles. Additionally, CORLANOR (ivabradine) and ARNI combinations such as sacubitril/valsartan have shown promising outcomes in reducing hospitalization and mortality rates.
Non-pharmacological strategies like sodium and fluid restriction, exercise, and patient education complement drug therapy. In cases where symptoms persist despite optimal medical therapy, implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy (CRT) are recommended to prevent arrhythmic events and improve heart function.
The DCM pipeline shows a steady evolution with multiple therapies targeting the root causes, especially in genetically driven forms. Companies like Bristol Myers Squibb, Rocket Pharmaceuticals, Berlin Cures, and others are advancing therapies aimed at cardiac remodeling, inflammation control, and gene correction. As novel candidates move through Phase II and III trials, the DCM market is expected to grow with an emphasis on precision medicine and long-term disease modification.
Dilated Cardiomyopathy Market Strengths
• The DCM market benefits from a well-defined treatment paradigm, including ACE inhibitors, beta-blockers, and newer agents like sacubitril/valsartan and ivabradine. Invasive therapies such as ICD and CRT implantation further enhance disease management and survival rates.
• Multiple biopharmaceutical companies are advancing novel therapies, including gene therapies and disease-modifying agents, with a strong focus on addressing the underlying etiology of DCM, particularly in familial and genetically linked cases.
Dilated Cardiomyopathy Market Weaknesses
• DCM can arise from various causes—genetic, idiopathic, or acquired—making it difficult to adopt a one-size-fits-all therapy. Most current treatments remain symptomatic, with limited availability of curative or targeted therapies.
• Many cases remain undiagnosed until the disease is advanced, especially in asymptomatic individuals or those in low-resource settings. This delays intervention, limits therapeutic outcomes, and hinders accurate epidemiological assessment.
Scope of the Dilated Cardiomyopathy Market Report
• Study Period: 2020–2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Dilated Cardiomyopathy Companies: Pfizer, Capricor Therapeutics, MyoKardia, Cumberland Pharmaceuticals, Berlin Cures, and others.
• Key Dilated Cardiomyopathy Therapies: Danicamtiv (MYK-491), BC007, DYSCORBAN (ifetroban), and others.
• Dilated Cardiomyopathy Therapeutic Assessment: Dilated Cardiomyopathy, currently marketed, and Dilated Cardiomyopathy emerging therapies
• Dilated Cardiomyopathy Market Dynamics: Dilated Cardiomyopathy market drivers and Dilated Cardiomyopathy market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Dilated Cardiomyopathy Unmet Needs, KOL’s views, Analyst’s views, Dilated Cardiomyopathy Market Access and Reimbursement
To learn more about the key players and advancements in the dilated cardiomyopathy treatment landscape, visit the Dilated Cardiomyopathy Market Analysis Report
Table of Contents
1. Dilated Cardiomyopathy Market Report Introduction
2. Executive Summary for Dilated Cardiomyopathy
3. SWOT analysis of Dilated Cardiomyopathy
4. Dilated Cardiomyopathy Patient Share (%) Overview at a Glance
5. Dilated Cardiomyopathy Market Overview at a Glance
6. Dilated Cardiomyopathy Disease Background and Overview
7. Dilated Cardiomyopathy Epidemiology and Patient Population
8. Country-Specific Patient Population of Dilated Cardiomyopathy
9. Dilated Cardiomyopathy Current Treatment and Medical Practices
10. Dilated Cardiomyopathy Unmet Needs
11. Dilated Cardiomyopathy Emerging Therapies
12. Dilated Cardiomyopathy Market Outlook
13. Country-Wise Dilated Cardiomyopathy Market Analysis (2020–2034)
14. Dilated Cardiomyopathy Market Access and Reimbursement of Therapies
15. Dilated Cardiomyopathy Market Drivers
16. Dilated Cardiomyopathy Market Barriers
17. Dilated Cardiomyopathy Appendix
18. Dilated Cardiomyopathy Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefit from market analysis to accelerate business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsightContact Person: Jatin VimalEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/
